salgrelide

Salgrelide (CP-730,690) is a discontinued small molecule phosphodiesterase 3 (PDE3) inhibitor that was developed by Pfizer. By inhibiting the PDE3 enzyme, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to increased intracellular levels of this secondary messenger. This mechanism typically results in vasodilation and the inhibition of platelet aggregation. Although PDE3 inhibitors as a class are frequently investigated for the treatment of acute heart failure and intermittent claudication, Pfizer discontinued the development of salgrelide before it reached market approval, and the specific primary indication intended for its clinical use remains officially unknown.